Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 0 | 250,000 | 646 | 0 | 0 |
| Gross Profit | N/A | 224,950 | 646 | N/A | N/A |
| Operating Expenses | 124,591 | 119,880 | 130,198 | 115,508 | 98,786 |
| Operating Income | -124,591 | 130,120 | -129,552 | -115,508 | -98,786 |
| Interest Expense | 4,175 | 9,610 | 9,499 | 6,909 | 3,919 |
| Other Income | -54,893 | -40,400 | 3,351 | 3,800 | -66,117 |
| Pre-tax Income | -183,659 | 80,110 | -135,700 | -118,617 | -168,822 |
| Net Income Continuous | -183,659 | 78,265 | -135,700 | -118,617 | -168,822 |
| Net Income | $-183,659 | $78,265 | $-135,700 | $-118,617 | $-168,822 |
| EPS Basic Total Ops | -2.32 | 1.06 | -1.79 | -1.57 | -2.29 |
| EPS Basic Continuous Ops | -2.32 | 1.07 | -1.79 | -1.57 | -2.29 |
| EPS Diluted Total Ops | -2.32 | 1.06 | -1.79 | -1.57 | -2.29 |
| EPS Diluted Continuous Ops | -2.32 | 1.07 | -1.79 | -1.57 | -2.29 |
| EBITDA(a) | $-123,837 | $135,460 | $-124,309 | $-111,832 | $-96,650 |